Citigroup’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $49.6K | Buy |
14,456
+10,119
| +233% | +$34.7K | ﹤0.01% | 4033 |
|
|
2025
Q1 | $9.67K | Sell |
4,337
-8,279
| -66% | -$18.5K | ﹤0.01% | 4430 |
|
|
2024
Q4 | $37K | Buy |
12,616
+7,382
| +141% | +$21.6K | ﹤0.01% | 4307 |
|
|
2024
Q3 | $13.6K | Sell |
5,234
-74,055
| -93% | -$193K | ﹤0.01% | 4449 |
|
|
2024
Q2 | $235K | Buy |
79,289
+75,249
| +1,863% | +$223K | ﹤0.01% | 3090 |
|
|
2024
Q1 | $18.3K | Sell |
4,040
-4,064
| -50% | -$18.4K | ﹤0.01% | 4303 |
|
|
2023
Q4 | $46.3K | Buy |
8,104
+3,842
| +90% | +$21.9K | ﹤0.01% | 3818 |
|
|
2023
Q3 | $19.6K | Sell |
4,262
-3,759
| -47% | -$17.3K | ﹤0.01% | 3702 |
|
|
2023
Q2 | $51.8K | Buy |
8,021
+2,884
| +56% | +$18.6K | ﹤0.01% | 3956 |
|
|
2023
Q1 | $38.7K | Sell |
5,137
-2,532
| -33% | -$19.1K | ﹤0.01% | 3692 |
|
|
2022
Q4 | $77.7K | Sell |
7,669
-2,409
| -24% | -$24.4K | ﹤0.01% | 3433 |
|
|
2022
Q3 | $100K | Sell |
10,078
-22,646
| -69% | -$225K | ﹤0.01% | 3389 |
|
|
2022
Q2 | $349K | Buy |
32,724
+21,702
| +197% | +$231K | ﹤0.01% | 2859 |
|
|
2022
Q1 | $107K | Sell |
11,022
-2,229
| -17% | -$21.6K | ﹤0.01% | 3693 |
|
|
2021
Q4 | $189K | Buy |
13,251
+7,471
| +129% | +$107K | ﹤0.01% | 3640 |
|
|
2021
Q3 | $116K | Sell |
5,780
-1,867
| -24% | -$37.5K | ﹤0.01% | 3622 |
|
|
2021
Q2 | $168K | Buy |
7,647
+7,447
| +3,724% | +$164K | ﹤0.01% | 3646 |
|
|
2021
Q1 | $7K | Buy |
+200
| New | +$7K | ﹤0.01% | 5128 |
|